The U.S. Court of Appeals for the Federal Circuit remanded Guardant Health’s patent dispute with TwinStrand Biosciences and the University of Washington to the Patent Trial and Appeal Board for further consideration. The case stems from a 2023 jury verdict finding Guardant willfully infringed duplex‑consensus sequencing patents and ordering royalties. The remand could alter the validity review of at least one patent and affect potential damages exposure tied to liquid‑biopsy sequencing methods.